Mobile app version of munafa.org.in
Login or Join
 Learn then Earn
stockMarketNEWS

 story : FDA declines to authorize fluvoxamine as a COVID-19 treatment #FinanceUSA #StockMarketNEWS The Food and Drug Administration said Monday that it won't authorize fluvoxamine, a generic treatment for

@stockMarketNEWS Tue 17 May, 2022

Posted in: #FinanceUSA #StockMarketNEWS

FDA declines to authorize fluvoxamine as a COVID-19 treatment #FinanceUSA #StockMarketNEWS
The Food and Drug Administration said Monday that it won't authorize fluvoxamine, a generic treatment for obsessive-compulsive disorder, as a COVID-19 therapy. "The FDA has determined that the data are insufficient to conclude that fluvoxamine may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization," the regulator said, citing the need to look at the totality of scientific data. A group of physicians led by the University of Minnesota's Dr. David Boulware in late 2021 formally requested that the FDA authorize fluvoxamine as a COVID-19 treatment. "I'm disappointed that FDA holds generics to different standards as big pharma, in this case using different definition of endpoints of what is a [COVID-19-related] 'hospitalization,'" Boulware tweeted Monday.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme